AstraZeneca, Aifa: “On safety at under 60 uncertainty margins”

AstraZeneca vaccine, thrombosis risk, second dose in Italy: news arrives from Aifa. “The safety of the administration of the AstraZeneca (Vaxzevria) vaccine in subjects under the age of 60 remains an open topic, and on which there is room for uncertainty”. Despite these uncertainties, regarding the second dose for the ‘under 60’ vaccinated with AstraZeneca, the Aifa Hemostasis and Thrombosis Working Group believes that “the completion of the vaccination schedule represents the strategy to combat the spread of the Sars-Cov-2 virus. which guarantees the best level of protection “. This is established by the in-depth document of the Hemostasis and Thrombosis Working Group of experts in coagulation pathologies on post-Covid thromboembolic complications with the AstraZeneca and Johnson & Johnson vaccines, appointed by the AIFA. Experts answer 10 questions, the last one concerns the existence of a rationale for deciding what to do with the second dose for subjects under 60 who have already taken the first dose of Vaxzevria.